Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177463 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1NCOA1CYP1A2CYP1B1 | |
| SCHEMBL276699 | 0.71 | MAPT (0.46) | KDM4EALDH1A1NCOA1CYP1A2NPC1 | |
| SCHEMBL29506237 | 0.71 | MAPT (0.46) | KDM4EALDH1A1NCOA1CYP1A2NPC1 | |
| SCHEMBL16806269 | 0.71 | ALDH1A1 (0.33) | ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL29506236 | 0.71 | MAPT (0.46) | KDM4EALDH1A1NCOA1CYP1A2NPC1 | |
| SCHEMBL1404660 | 0.69 | LMNA (0.47) | KDM4EALDH1A1NCOA1CYP1A2TP53 | |
| SCHEMBL27333832 | 0.69 | MAPT (0.44) | KDM4EALDH1A1NCOA1CYP1A2NPC1 | |
| Hydrochloric Acid SCHEMBL22092050 | 0.69 | MAPT (0.44) | KDM4EALDH1A1NCOA1CYP1A2NPC1 | |
| SCHEMBL1810060 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL15228365 | 0.68 | LMNA (0.45) | KDM4EALDH1A1NCOA1CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027601-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2016-06-08 | — | — | EP | claimed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | GENENTECH, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-11325912-B2 | Regio-selective synthesis of imidazo[1,2-a]pyrimidines | GENENTECH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3901145-A1 | DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE SYNTHESIS OF IMAGING AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-20200369670-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020227576-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200297875-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10675367-B2 | Deuterated compounds and uses thereof | GENENTECH INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190201561-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10076581-B2 | Deuterated compounds and uses thereof | GENENTECH, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3143011-A1 | DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS | F. Hoffmann-La Roche AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20160250358-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3027601-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015173225-A1 | DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| EP-2741609-A1 | NEUROPROTECTIVE POLYPHENOL ANALOGS | Salk Institute for Biological Studies (US) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013025484-A1 | POLYPHENOL ANALOGS TO TREAT ISCHEMIA | LAPCHAK PAUL A (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013025498-A1 | NEUROPROTECTIVE POLYPHENOL ANALOGS | SCHUBERT DAVID R (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297875-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | KDM4E 2907/4885ALDH1A1 1363/4885NCOA1 1373/4885 |
| US-10076581-B2 | Deuterated compounds and uses thereof | SLC10A1, AVPR2, SLC9B2 | KDM4E 2907/4885ALDH1A1 1363/4885NCOA1 1373/4885 |
| US-11325912-B2 | Regio-selective synthesis of imidazo[1,2-a]pyrimidines | CDK2, P2RY1, P2RX1 | KDM4E 2940/4885ALDH1A1 1958/4885NCOA1 2448/4885 |
| US-20200369670-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES | CDK2, P2RY1, P2RX1 | KDM4E 2940/4885ALDH1A1 1958/4885NCOA1 2448/4885 |
| US-20190201561-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | KDM4E 2907/4885ALDH1A1 1363/4885NCOA1 1373/4885 |
| US-20160250358-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | SLC10A1, AVPR2, SLC9B2 | KDM4E 2907/4885ALDH1A1 1363/4885NCOA1 1373/4885 |
| US-10675367-B2 | Deuterated compounds and uses thereof | SLC10A1, AVPR2, SLC9B2 | KDM4E 2907/4885ALDH1A1 1363/4885NCOA1 1373/4885 |
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | SLC10A1, SLC9B2, RXFP1 | KDM4E 2894/4885ALDH1A1 1909/4885NCOA1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.